Published in Int J Cancer on January 29, 1999
Mesenchymal-endothelial transition contributes to cardiac neovascularization. Nature (2014) 1.44
Selective enrichment of newly synthesized proteins for quantitative secretome analysis. Nat Biotechnol (2012) 1.32
SILEC: a protocol for generating and using isotopically labeled coenzyme A mass spectrometry standards. Nat Protoc (2011) 1.08
Action of polystyrene nanoparticles of different sizes on lysosomal function and integrity. Part Fibre Toxicol (2012) 0.88
Role of HGF/c-Met in serum-starved ARPE-19 cells. Korean J Ophthalmol (2007) 0.84
Disparate effects of serum on basal and evoked NFAT activity in primary astrocyte cultures. Neurosci Lett (2009) 0.80
The role of Misshapen NCK-related kinase (MINK), a novel Ste20 family kinase, in the IRES-mediated protein translation of human enterovirus 71. PLoS Pathog (2015) 0.78
Capturing the dynamic nascent transcriptome during acute cellular responses: The serum response. Biol Open (2016) 0.77
High-frequency ultrasound detection of cell death: Spectral differentiation of different forms of cell death in vitro. Oncoscience (2016) 0.75
Clinical testing of the radiosensitizer Ro 07-0582: experience with multiple doses. Br J Cancer (1977) 5.58
Clinical testing of the radiosensitiser Ro-07-0582. I. Dose tolerance, serum and tumour concentrations. Clin Radiol (1976) 3.55
Effect of hyperthermia on differential cytotoxicity of a hypoxic cell radiosensitizer, Ro-07-0582, on mammalian cells in vitro. Br J Cancer (1977) 3.51
Electron-affinic sensitization. VII. A correlation between structures, one-electron reduction potentials, and efficiencies of nitroimidazoles as hypoxic cell radiosensitizers. Radiat Res (1976) 3.44
Electron affinic sensitization. V. Radiosensitization of hypoxic bacteria and mammalian cells in vitro by some nitroimidazoles and nitropyrazoles. Radiat Res (1974) 2.61
Radiosensitizers of hypoxic cells in solid tumors. Cancer Treat Rev (1976) 2.33
Chemical radiosensitization of hypoxic cells. Br Med Bull (1973) 2.10
Radiation-induced energy migration within solid DNA: the role of misonidazole as an electron trap. Radiat Res (1990) 2.01
Time-resolved oxygen effects in irradiated bacteria and mammalian cells: a rapid-mix study. Radiat Res (1975) 1.63
The interaction of misonidazole with radiation, chemotherapeutic agents, or heat: a preliminary report. Cancer Clin Trials (1980) 1.54
Mammalian cell toxicity of nitro compounds : dependence upon reduction potential. Biochem Biophys Res Commun (1976) 1.53
Structure-activity relationships in the development of hypoxic cell radiosensitizers. I. Sensitization efficiency. Int J Radiat Biol Relat Stud Phys Chem Med (1979) 1.47
Low-dose hyper-radiosensitivity: a consequence of ineffective cell cycle arrest of radiation-damaged G2-phase cells. Radiat Res (2004) 1.41
Hypoxia: new mechanisms for old? Int J Radiat Oncol Biol Phys (1991) 1.40
The toxicity of the radiosensitizer misonidazole towards hypoxic cells in vitro: a model for mouse and man. Br J Radiol (1978) 1.40
Expression of dose in neutron therapy. Radiother Oncol (1990) 1.38
The response of Chinese hamster V79 cells to low radiation doses: evidence of enhanced sensitivity of the whole cell population. Radiat Res (1993) 1.30
Pharmacokinetics of nicotinamide and its effect on blood pressure, pulse and body temperature in normal human volunteers. Radiother Oncol (1992) 1.27
Cytotoxicity of adriamycin on aerobic and hypoxic chinese hamster V79 cells in vitro. Br J Cancer (1980) 1.22
A therapeutic benefit from combining normobaric carbogen or oxygen with nicotinamide in fractionated X-ray treatments. Radiother Oncol (1991) 1.18
Clinical evidence of hypersensitivity to low doses in radiotherapy. Radiother Oncol (1996) 1.17
Electron affinic sensitization. II. Para-nitroacetophenone: a radiosensitizer for anoxic bacterial and mammalian cells. Int J Radiat Biol Relat Stud Phys Chem Med (1971) 1.17
Factors affecting sensitivity to EO9 in rodent and human tumour cells in vitro: DT-diaphorase activity and hypoxia. Eur J Cancer (1994) 1.15
Toxicity of nitro compounds toward hypoxic mammalian cells in vitro: dependence on reduction potential. J Natl Cancer Inst (1980) 1.14
Electron-affinic sensitization. I. A structural basis for chemical radiosensitizers in bacteria. Int J Radiat Biol Relat Stud Phys Chem Med (1969) 1.14
Automated counting of mammalian cell colonies. Phys Med Biol (2001) 1.13
Thermotolerance in chinese hamster cells under oxic conditions after chronic culture under hypoxia. Br J Cancer (1981) 1.12
Low dose hypersensitivity in the T98G human glioblastoma cell line. Int J Radiat Biol (1999) 1.12
Low dose hyper-radiosensitivity and increased radioresistance in mammalian cells. Int J Radiat Biol (1997) 1.11
Radiation sensitization and chemopotentiation: RSU 1069, a compound more efficient than misonidazole in vitro and in vivo. Br J Cancer (1984) 1.11
Bioreductive drugs and the selective induction of tumour hypoxia. Br J Cancer (1990) 1.10
The response of spontaneous and transplantable murine tumors to vasoactive agents measured by 31P magnetic resonance spectroscopy. Int J Radiat Oncol Biol Phys (1992) 1.10
The sensitivity of human tumour cells to quinone bioreductive drugs: what role for DT-diaphorase? Biochem Pharmacol (1992) 1.10
Heterocyclic mono-N-oxides with potential applications as bioreductive anti-tumour drugs: Part 1. 8-Alkylamino-substituted phenylimidazo [1,2-a] quinoxalines. Anticancer Drug Des (1993) 1.08
Modification of energy metabolism and radiation response of a murine tumour by changes in nitric oxide availability. Biochem Biophys Res Commun (1993) 1.07
Low-dose hypersensitivity after fractionated low-dose irradiation in vitro. Int J Radiat Biol (2001) 1.07
Combination studies with misonidazole and a cis-platinum complex: cytotoxicity and radiosensitization in vitro. Br J Cancer (1980) 1.06
Magnetic resonance imaging and spectroscopy of combretastatin A4 prodrug-induced disruption of tumour perfusion and energetic status. Br J Cancer (1998) 1.05
Hypoxic cell sensitizers for radiotherapy. Int J Radiat Oncol Biol Phys (1978) 1.05
Potentiation of the anti-tumour effect of melphalan by the vasoactive agent, hydralazine. Br J Cancer (1988) 1.04
Role of apoptosis in low-dose hyper-radiosensitivity. Radiat Res (2007) 1.04
Hypoxic cell sensitisers in radiotherapy. Lancet (1976) 1.03
The response of human glioma cell lines to low-dose radiation exposure. Int J Radiat Biol (1999) 1.02
Importance of P450 reductase activity in determining sensitivity of breast tumour cells to the bioreductive drug, tirapazamine (SR 4233). Br J Cancer (1995) 1.02
Optimizing radiation-responsive gene promoters for radiogenetic cancer therapy. Gene Ther (2002) 1.02
Induction of hypoxia in experimental murine tumors by the nitric oxide synthase inhibitor, NG-nitro-L-arginine. Cancer Res (1994) 1.01
Effect of hydralazine in spontaneous tumours assessed by oxygen electrodes and 31P-magnetic resonance spectroscopy. Br J Cancer Suppl (1996) 1.00
Increasing the effect of photodynamic therapy on the RIF-1 murine sarcoma, using the bioreductive drugs RSU1069 and RB6145. Br J Cancer (1992) 1.00
A posteffect of oxygen in irradiated bacteria: a submillisecond fast mixing study. Radiat Res (1973) 0.99
RSU 1069, a nitroimidazole containing an aziridine group. Bioreduction greatly increases cytotoxicity under hypoxic conditions. Biochem Pharmacol (1986) 0.98
Structure-activity relationships in the development of hypoxic cell radiosensitizers. II. Cytotoxicity and therapeutic ratio. Int J Radiat Biol Relat Stud Phys Chem Med (1979) 0.98
Manipulation and exploitation of the tumour environment for therapeutic benefit. Int J Radiat Biol (1994) 0.97
Radiosensitization in vivo: a study with an homologous series of 2-nitroimidazoles. Int J Radiat Biol Relat Stud Phys Chem Med (1983) 0.97
Relationship between radiation-induced low-dose hypersensitivity and the bystander effect. Radiat Res (2002) 0.97
An association between the radiation-induced arrest of G2-phase cells and low-dose hyper-radiosensitivity: a plausible underlying mechanism? Radiat Res (2003) 0.96
Hypersensitivity of a human tumour cell line to very low radiation doses. Int J Radiat Biol (1993) 0.95
A purpose-built iodine-125 irradiation plaque for low dose rate low energy irradiation of cell lines in vitro. Br J Radiol (2001) 0.95
Hypoxia-mediated nitro-heterocyclic drugs in the radio- and chemotherapy of cancer. An overview. Biochem Pharmacol (1986) 0.94
Growth of fibroblasts as a potential confounding factor in soft agar clonogenic assays for tumour cell radiosensitivity. Radiother Oncol (1994) 0.94
RSU 1069, a 2-nitroimidazole containing an alkylating group: high efficiency as a radio- and chemosensitizer in vitro and in vivo. Int J Radiat Oncol Biol Phys (1984) 0.94
The development of some nitroimidazoles as hypoxic cell sensitizers. Cancer Clin Trials (1980) 0.93
Rapid mixing in radiobiology. Nature (1968) 0.92
Phosphomonoester is associated with proliferation in human breast cancer: a 31P MRS study. Br J Cancer (1993) 0.91
Induction of tumour hypoxia by a vasoactive agent. A combined NMR and radiobiological study. FEBS Lett (1989) 0.91
Evidence for the involvement of DNA-dependent protein kinase in the phenomena of low dose hyper-radiosensitivity and increased radioresistance. Int J Radiat Biol (2002) 0.91
The effects of three bioreductive drugs (mitomycin C, RSU-1069 and SR4233) on cell lines selected for their sensitivity to mitomycin C or ionising radiation. Br J Cancer (1990) 0.90
Oral (po) dosing with RSU 1069 or RB 6145 maintains their potency as hypoxic cell radiosensitizers and cytotoxins but reduces systemic toxicity compared with parenteral (ip) administration in mice. Int J Radiat Oncol Biol Phys (1991) 0.90
Hypoxia- and radiation-activated Cre/loxP 'molecular switch' vectors for gene therapy of cancer. Gene Ther (2006) 0.90
Hypersensitive response of normal human lung epithelial cells at low radiation doses. Int J Radiat Biol (1994) 0.90
Analogues of RSU-1069: radiosensitization and toxicity in vitro and in vivo. Int J Radiat Oncol Biol Phys (1986) 0.90
The translational research chain: is it delivering the goods? Int J Radiat Oncol Biol Phys (2001) 0.90
In vivo 31P nuclear magnetic resonance spectroscopy of experimental murine tumours and human tumour xenografts: effects of blood flow modification. Br J Cancer (1991) 0.89
A novel human stress response-related gene with a potential role in induced radioresistance. Radiat Res (1999) 0.89
Might intrinsic radioresistance of human tumour cells be induced by radiation? Int J Radiat Biol (1996) 0.89
31P magnetic resonance spectroscopy as a predictor of efficacy in photodynamic therapy using differently charged zinc phthalocyanines. Br J Cancer (1999) 0.88
The role of DT-diaphorase in determining the sensitivity of human tumor cells to tirapazamine (SR 4233). Int J Radiat Oncol Biol Phys (1994) 0.88
Misonidazole in fractionated radiotherapy: are many small fractions best? Br J Radiol (1980) 0.88
Potentiation of melphalan activity against a murine tumour by nitroimidazole compounds. Br J Cancer (1982) 0.88
Induction of tumour hypoxia post-irradiation: a method for increasing the sensitizing efficiency of misonidazole and RSU 1069 in vivo. Int J Radiat Biol (1989) 0.88
The elimination of low-dose hypersensitivity in Chinese hamster V79-379A cells by pretreatment with X rays or hydrogen peroxide. Radiat Res (1995) 0.88
Hypoxia-mediated drugs for radiation and chemotherapy. Cancer (1981) 0.87
Technetium-99m HMPAO and SPECT in the assessment of blood flow in human lung tumours. Br J Cancer (1989) 0.87
Hypoxia facilitates tumour cell detachment by reducing expression of surface adhesion molecules and adhesion to extracellular matrices without loss of cell viability. Br J Cancer (1998) 0.87
Radiosensitizing and cytotoxicity studies with CB 1954 (2,4-dinitro-5-aziridinylbenzamide). Radiat Res (1981) 0.86
Radiation response of murine eccrine sweat glands. Radiother Oncol (1995) 0.86
Cellular response to low-dose irradiation. Clin Oncol (R Coll Radiol) (1998) 0.86
Structure-activity relationships in the development of hypoxic cell radiosensitizers. III. Effects of basic substituents in nitroimidazole sidechains. Int J Radiat Biol Relat Stud Phys Chem Med (1980) 0.86
The use of 'top-up' experiments to investigate the effect of very small doses per fraction in mouse skin. Int J Radiat Biol Relat Stud Phys Chem Med (1986) 0.86
Dual function nitroimidazoles less toxic than RSU 1069: selection of candidate drugs for clinical trial (RB 6145 and/or PD 130908. Int J Radiat Oncol Biol Phys (1992) 0.86
Induction of hypoxia in normal and malignant tissues by changing the oxygen affinity of hemoglobin--implications for therapy. Int J Radiat Oncol Biol Phys (1986) 0.86
Time effects in molecular radiation biology. Radiat Environ Biophys (1980) 0.85
The Klaas Breur Lecture. Radiation, hypoxia and genetic stimulation: implications for future therapies. Radiother Oncol (1997) 0.85
Low-dose hyper-radiosensitivity is not caused by a failure to recognize DNA double-strand breaks. Radiat Res (2006) 0.85
Enhancement of tumor radiosensitivity and reduced hypoxia-dependent binding of a 2-nitroimidazole with normobaric oxygen and carbogen: a therapeutic comparison with skin and kidneys. Int J Radiat Oncol Biol Phys (1992) 0.85
Indolequinone antitumor agents: reductive activation and elimination from (5-methoxy-1-methyl-4,7-dioxoindol-3-yl)methyl derivatives and hypoxia-selective cytotoxicity in vitro. J Med Chem (1998) 0.85
A generalized formulation of the 'incomplete-repair' model for cell survival and tissue response to fractionated low dose-rate irradiation. Int J Radiat Biol (1990) 0.84
Effect of subsequent acute-dose irradiation on cell survival in vitro following low dose-rate exposures. Int J Radiat Biol (2002) 0.84
Modification of metabolism of transplantable and spontaneous murine tumors by the nitric oxide synthase inhibitor, nitro-L-arginine. Int J Radiat Oncol Biol Phys (1994) 0.84